Personalized medicine in lung cancer: what we need to know
TSK Mok - Nature reviews Clinical oncology, 2011 - nature.com
Lung cancer is a complex and often fatal disease. The recent discovery of activating
mutations in EGFR and fusion genes involving ALK has set the stage for personalized …
mutations in EGFR and fusion genes involving ALK has set the stage for personalized …
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical …
D Planchard, KH Brown, DW Kim, SW Kim… - Cancer Chemotherapy …, 2016 - Springer
Abstract Purpose Osimertinib (AZD9291) 80 mg once daily is approved by the US FDA for
the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has …
the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has …
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
T Vaclova, U Grazini, L Ward, D O'Neill… - Nature …, 2021 - nature.com
Advanced non-small-cell lung cancer (NSCLC) patients with EGFR T790M-positive tumours
benefit from osimertinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR …
benefit from osimertinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR …
Circulating tumor DNA detection in lung cancer patients before and after surgery
N Guo, F Lou, Y Ma, J Li, B Yang, W Chen, H Ye… - Scientific reports, 2016 - nature.com
Circulating tumor DNA (ctDNA) in peripheral blood is a “liquid biopsy” that contains
representative tumor information including gene mutations. Additionally, repeated ctDNA …
representative tumor information including gene mutations. Additionally, repeated ctDNA …
Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
Z Wang, R Chen, S Wang, J Zhong, M Wu, J Zhao… - PloS one, 2014 - journals.plos.org
Background Among advanced non-small cell lung cancer (NSCLC) patients with an
acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …
acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR …
Structure–activity relationship studies based on quinazoline derivatives as EGFR kinase inhibitors (2017–present)
The epidermal growth factor receptor (EGFR) plays a critical role in the tumorigenesis of
various forms of cancer. Targeting the mutant forms of EGFR has been identified as an …
various forms of cancer. Targeting the mutant forms of EGFR has been identified as an …
[HTML][HTML] Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
NMA Wright, GD Goss - Translational Lung Cancer Research, 2019 - ncbi.nlm.nih.gov
Mutations in the epidermal growth factor receptor (EGFR) gene are the most common
targetable genomic drivers of non-small cell lung cancer (NSCLC), occurring in …
targetable genomic drivers of non-small cell lung cancer (NSCLC), occurring in …
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
JJ Yang, J Fang, YQ Shu, JH Chang, GY Chen… - Investigational New …, 2021 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are recommended
first-line treatments in EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) …
first-line treatments in EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) …
Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going
A Russo, T Franchina, GRR Ricciardi… - Critical reviews in …, 2017 - Elsevier
The therapeutic landscape of Non Small Lung Cancer (NSCLC) has been profoundly
changed over the last decade with the clinical introduction of Epidermal Growth Factor …
changed over the last decade with the clinical introduction of Epidermal Growth Factor …
Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor …
PA Dickinson, MV Cantarini, J Collier, P Frewer… - Drug Metabolism and …, 2016 - ASPET
Preclinical and clinical studies were conducted to determine the metabolism and
pharmacokinetics of osimertinib and key metabolites AZ5104 and AZ7550. Osimertinib was …
pharmacokinetics of osimertinib and key metabolites AZ5104 and AZ7550. Osimertinib was …